Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2015 1
2016 8
2017 21
2018 30
2019 7
2020 4
2021 1
2022 4
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Results by year

Filters applied: . Clear all
Page 1
HAART in HIV/AIDS Treatments: Future Trends.
Lu DY, Wu HY, Yarla NS, Xu B, Ding J, Lu TR. Lu DY, et al. Among authors: yarla ns. Infect Disord Drug Targets. 2018;18(1):15-22. doi: 10.2174/1871526517666170505122800. Infect Disord Drug Targets. 2018. PMID: 28474549 Review.
Tumor-intrinsic NLRP3-HSP70-TLR4 axis drives premetastatic niche development and hyperprogression during anti-PD-1 immunotherapy.
Theivanthiran B, Yarla N, Haykal T, Nguyen YV, Cao L, Ferreira M, Holtzhausen A, Al-Rohil R, Salama AKS, Beasley GM, Plebanek MP, DeVito NC, Hanks BA. Theivanthiran B, et al. Among authors: yarla n. Sci Transl Med. 2022 Nov 23;14(672):eabq7019. doi: 10.1126/scitranslmed.abq7019. Epub 2022 Nov 23. Sci Transl Med. 2022. PMID: 36417489 Free PMC article.
Ebola Therapeutic Study and Future Directions.
Lu DY, Wu HY, Yarla NS, Lu TR, Xu B, Jian-Ding. Lu DY, et al. Among authors: yarla ns. Infect Disord Drug Targets. 2019;19(1):17-29. doi: 10.2174/1871526518666180813160348. Infect Disord Drug Targets. 2019. PMID: 30101721 Review.
Drug Combination in Clinical Cancer Treatments.
Lu DY, Lu TR, Yarla NS, Wu HY, Xu B, Ding J, Zhu H. Lu DY, et al. Among authors: yarla ns. Rev Recent Clin Trials. 2017;12(3):202-211. doi: 10.2174/1574887112666170803145955. Rev Recent Clin Trials. 2017. PMID: 28782482 Review.
Recent Advancement against Neglected Diseases.
Scotti L, Scotti MT, Yarla NS. Scotti L, et al. Among authors: yarla ns. Curr Top Med Chem. 2018;18(18):1520-1521. doi: 10.2174/156802661818181119142905. Curr Top Med Chem. 2018. PMID: 30543157
Galectins-A Potential Target for Cardiovascular Therapy.
Ashraf GM, Perveen A, Zaidi SK, Ahmad A, Shakil S, Firoz CK, Jabir NR, Hassan I, Khan TA, Yarla NS, Tabrez S. Ashraf GM, et al. Among authors: yarla ns. Curr Vasc Pharmacol. 2017;15(4):296-312. doi: 10.2174/1570161115666170201113046. Curr Vasc Pharmacol. 2017. PMID: 28155611 Review.
Can Probiotics Cure Inflammatory Bowel Diseases?
Korada SK, Yarla NS, Bishayee A, Aliev G, Aruna Lakshmi K, Arunasree MK, Dananajaya BL, Mishra V. Korada SK, et al. Among authors: yarla ns. Curr Pharm Des. 2016;22(7):904-17. doi: 10.2174/1381612822666151209153249. Curr Pharm Des. 2016. PMID: 26648465 Review.
Frontier View on Nanotechnological Strategies for Neuro-therapy.
Azhar A, Ashraf GM, Zia Q, Ansari SA, Perveen A, Hafeez A, Saeed M, Kamal MA, Alexiou A, Ganash M, Yarla NS, Baeesa SS, Alfiky MM, Bajouh OS. Azhar A, et al. Among authors: yarla ns. Curr Drug Metab. 2018;19(7):596-604. doi: 10.2174/1389200219666180305144143. Curr Drug Metab. 2018. PMID: 29512448 Review.
71 results